Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03066011 · ClinicalTrials.gov registry record
Registry of Patients Treated With Systemic Mold-Active Triazoles
A clinical trial, sponsored by Astellas Pharma Global Development.
- Completed
- Registry status
- 2,015
- Enrollment target
NCT03066011: Completed study, sponsored by Astellas Pharma Global Development.
NCT03066011 is a clinical trial that has completed, run by Astellas Pharma Global Development. The registered enrollment target is 2,015 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03066011 has completed, sponsored by Astellas Pharma Global Development.
- COMPLETED
- Registry status
- 2,015 participants
- Enrollment target
Study Summary
The purpose of this study is to describe representative real-world patterns of care for the management of invasive fungal infections (IFIs), including invasive mold infection (IMI). Specifically, the study goals are to examine real world patient characteristics and treatment patterns, associated healthcare resource utilization, and outcomes associated with use of mold-active triazoles (MATs) to treat invasive fungal infections (IFIs).
Primary Outcome
Assessments of patient patterns of care will be summarized by MAT treatment at baseline and overall.
Interventions
- DRUG Posaconazole
- DRUG Voriconazole
- DRUG Isavuconazonium sulfate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,015 participants |
| Start Date | 2017-03-16 |
| Est. Completion | 2020-04-24 |
What the finished NCT03066011 record still lists
NCT03066011 is an observational study that tracks outcomes without assigning an intervention. Its 2,015 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 3 interventions - of which Posaconazole is the first listed.
NCT03066011 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03066011 about?
NCT03066011 is a clinical study titled "Registry of Patients Treated With Systemic Mold-Active Triazoles". The purpose of this study is to describe representative real-world patterns of care for the management of invasive fungal infections (IFIs), including invasive mold infection (IMI). Specifically, the study goals are to examine real world patient characteristics and treatment patterns, associated hea...
What is the current status of trial NCT03066011?
This trial is currently completed. The enrollment target is 2,015 participants. The study started on 2017-03-16. Estimated completion is 2020-04-24.
What interventions are being tested in trial NCT03066011?
The interventions under investigation include: Posaconazole (DRUG), Voriconazole (DRUG), Isavuconazonium sulfate (DRUG).
Who is sponsoring clinical trial NCT03066011?
This trial is sponsored by Astellas Pharma Global Development, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05059444 · 2,020 participants
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
- NCT04604509 · 2,010 participants · Phase 4
Nicotine Replacement Therapy, Counseling, Varenicline, and Bupropion for Smoking Cessation, the PISCES I Trial
- NCT04100564 · 2,009 participants · NA
LITES Task Order 0005 Prehospital Airway Control Trial (PACT)
- NCT04216732 · 2,030 participants
Natural History of Medullary Thyroid Cancer to Inform Advanced Disease Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI